Cytrellis Biosystems, Inc. has unveiled the next generation of its revolutionary skin treatment system, Ellacor 2.0, under the leadership of newly-appointed President and CEO Denise Dajles, DEng, MSc. This cutting-edge device builds upon the company’s original Micro-Coring technology, offering enhanced capabilities in minimally invasive aesthetic treatments.
Ellacor 2.0 is the result of years of development, drawing insights from thousands of procedures performed since the device’s initial FDA clearance in 2021. With this new iteration, Cytrellis aims to further establish itself as a leader in medical aesthetics by improving outcomes, reducing recovery time, and optimizing the patient experience.
Ellacor 2.0: A Breakthrough in Non-Surgical Skin Treatments
The Ellacor system is the first and only FDA-cleared minimally invasive solution for skin removal, specifically designed to target moderate to severe wrinkles, particularly on the mid and lower face. Unlike traditional surgical methods or thermal energy treatments, Ellacor employs hollow needles to remove up to 8% of the skin in a single office procedure. This unique process stimulates natural collagen regeneration, leading to a noticeable reduction in wrinkles without the risk of scarring.
According to Dajles, the improvements in Ellacor 2.0 are based on valuable feedback from both practitioners and patients. “We’ve incorporated these insights to enhance every aspect of the treatment, including faster coring, more precise procedures, and greater ease of use,” she explained.
Key Enhancements in Ellacor 2.0
Cytrellis has implemented a series of updates in Ellacor 2.0 designed to improve the system’s efficiency, reduce downtime, and deliver consistent, superior results. These include:
Improved Needle Cartridge Design: The updated system allows for faster and more precise coring, cutting procedure time by approximately 35%.
Enhanced Software: New software guides practitioners through the process, ensuring consistency and simplifying the procedure.
Comprehensive Protocols: Standardized pre- and post-care recommendations are provided to ensure optimal results for a broader range of patients.
Dajles highlighted that these advancements were made with patient and provider feedback in mind, resulting in a 60% reduction in downtime. This change allows patients to resume their daily activities more quickly while maintaining high satisfaction levels.
Clinical Evidence and Positive Industry Reception
Ellacor’s technology has shown promising clinical results, with studies reporting up to a 90% improvement in the appearance of fine lines and wrinkles. The non-thermal, mechanical process offers a safer, more predictable alternative to traditional surgical methods, making it an appealing option for patients seeking effective, minimally invasive treatments.
The system has been well-received by dermatology and plastic surgery professionals. “Practitioners appreciate how Ellacor 2.0 incorporates their feedback, which has led to both a more efficient procedure and better patient outcomes,” Dajles noted.
With its innovative design and demonstrated efficacy, Ellacor 2.0 is poised to shape the future of aesthetic treatments, providing a new option for patients seeking non-invasive solutions to skin aging.
Related topics
